Cash and cash equivalents and short-term financial assets

6 Months Ended

Jun. 30, 2026

Cash and cash equivalents and short-term financial assets

Cash and cash equivalents and short-term financial assets

10.Cash and cash equivalents and short-term financial assets

The following table summarizes AC Immune’s cash and cash equivalents and short-term financial assets as of June 30, 2026 and December 31, 2025:


		As of
In CHF thousands		June 30, 2026		December 31, 2025
Cash and cash equivalents		27,757		26,795
Total cash and cash equivalents		27,757		26,795


		As of
In CHF thousands		June 30, 2026		December 31, 2025
Short-term financial assets due in one year or less		47,600		64,617
Total short-term financial assets		47,600		64,617

For the six months ended June 30, 2026, the net proceeds reported as investing cash flows from the maturity of investments in short-term financial assets amounted to CHF 17.0 million, compared to net proceeds from the maturity of investments of CHF 27.8 million in the prior comparable period.